Abstract 445P
Background
Trastuzumab emtansine (T-DM1) is recommended as the standard treatment of second-line therapy of HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. However, subsequent therapeutics after T-DM1 failure remain controversial. This study investigated the effectiveness and safety of tyrosine kinase inhibitors (TKIs)-based therapy in HER2-positive MBC with T-DM1 resistance.
Methods
From September 2018 to October 2021, 53 patients with HER2-positive MBC who received TKIs-based therapy after T-DM1 failure were enrolled in this multicenter real-world study. The primary endpoint was progression free survival (PFS). Secondary endpoints included objective response rate (ORR), overall survival (OS), clinical benefit rate (CBR) and safety.
Results
53 patients received TKIs-based therapy in 2 or later line treatment. The median PFS of TKIs-based therapy was 11.9 months (95% CI 7.9-15.9). ORR and CBR were 19.6% and 72.5%, respectively. A median PFS of 10.5 months (95% CI 7.5-13.5) and an intracranial ORR of 33.3% were observed among patients with brain metastasis (n=12). A better PFS was observed among patients with pyrotinib (n=21) compared with lapatinib (n=30), and patients who derived favorable benefit from T-DM1 (PFS ≥ 6 months). Hormone receptor status (HR) and T-DM1 response were independent indicators for curative effect of TKIs-based therapy. The most commonly adverse events were thrombocytopenia (23.6%), diarrhea (15.7%), leucopenia (15.7%), and hand-foot syndrome (15.7%).
Conclusions
TKIs-based therapy showed promising efficacy and safety in patients with HER2-positive MBC after T-DM1 failure, including those with brain metastases. Patients who benefited from prior T-DM1 achieved a significantly longer PFS in subsequent TKIs-based therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Province Hospital.
Funding
Y. Yin.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03
393P - Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Presenter: Kevin Kalinsky
Session: Poster session 03
394P - CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Presenter: Francesco Pantano
Session: Poster session 03
395P - Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Kyung Jung
Session: Poster session 03
396P - Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
Presenter: Kevin Punie
Session: Poster session 03
398P - A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin (PLD) and toripalimab in metastatic triple-negative breast cancer (TNBC): IN10018-010
Presenter: Xichun Hu
Session: Poster session 03
399P - Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Presenter: weina shen
Session: Poster session 03
400P - The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
Presenter: Roberta Scafetta
Session: Poster session 03
401P - Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Presenter: Yehui Shi
Session: Poster session 03